SCHEMBL2919086

SCHEMBL2919086

Clc1ccnc2sccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.45
CHEK1 O14757 1/20 0.45
AURKA O14965 1/20 0.45
DAPK3 O43293 1/20 0.45
JAK2 O60674 1/20 0.45
MAP4K4 O95819 1/20 0.45
ABL1 P00519 1/20 0.45
NTRK1 P04629 1/20 0.45
LCK P06239 1/20 0.45
FYN P06241 1/20 0.45
CSF1R P07333 1/20 0.45
RET P07949 1/20 0.45
IGF1R P08069 1/20 0.45
MET P08581 1/20 0.45
PDGFRB P09619 1/20 0.45
PIM1 P11309 1/20 0.45
FGFR1 P11362 1/20 0.45
PRKACA P17612 1/20 0.45
LTK P29376 1/20 0.45
KDR P35968 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7255700 0.87 CHEK1 (0.49) DYRK1ACHEK1AURKADAPK3JAK2
SCHEMBL4157610 0.77 CHEK1 (0.45) DYRK1ACHEK1AURKADAPK3JAK2
SCHEMBL31278844 0.77 CHEK1 (0.45) DYRK1ACHEK1AURKADAPK3JAK2
SCHEMBL422299 0.73 CCR1 (0.48) DYRK1ACHEK1AURKADAPK3JAK2
SCHEMBL3608593 0.73 CHEK1 (0.45) DYRK1ACHEK1AURKADAPK3JAK2
SCHEMBL22270837 0.73 CHEK1 (0.45) DYRK1ACHEK1AURKADAPK3JAK2
SCHEMBL16539918 0.73 DYRK1A (0.45) DYRK1ACHEK1AURKADAPK3JAK2
SCHEMBL966279 0.73 DYRK1A (0.55) DYRK1ACHEK1AURKADAPK3JAK2
SCHEMBL9704 0.71 CHEK1 (0.59) DYRK1ACHEK1AURKADAPK3JAK2
SCHEMBL3971484 0.70 KDM4E (0.40) DYRK1AMAP4K4PIM1CLK2MAP4K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340565-A1 CD73 INHIBITOR COMPOUNDS ADORX THERAPEUTICS LTD (GB) 2025-11-06 US disclosed
US-12404279-B2 Deubiquitinase inhibitors and methods of use thereof MOLECURE S.A. (PL) 2025-09-02 US disclosed
EP-4532495-A1 CD73 INHIBITOR COMPOUNDS Adorx therapeutics Limited (GB) 2025-04-09 EP disclosed
EP-4452984-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF Molecure S.A. (PL) 2024-10-30 EP disclosed
EP-3558969-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-09-18 EP disclosed
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2024-09-03 US disclosed
US-20240287076-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE C4 THERAPEUTICS, INC. 2024-08-29 US disclosed
WO-2024131942-A1 CYCLOPROPANE TLR7 AND TLR8 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 上海深势唯思科技有限责任公司 2024-06-27 WO disclosed
CN-118239959-A Cyclopropane TLR7 and 8 inhibitor and preparation method and application thereof 上海深势唯思科技有限责任公司 2024-06-25 CN disclosed
CN-118239926-A TLR7 and 8 inhibitors, preparation method and application thereof 上海深势唯思科技有限责任公司 2024-06-25 CN disclosed
US-20030162784-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2003-08-28 US disclosed
US-6579879-B2 Pyridazinone aldose reductase inhibitors PFIZER INC 2003-06-17 US disclosed
WO-2003000194-A2 THIENOPYRIDINE AND THIENOPYRIMIDINE ANTICANCER AGENTS PFIZER INC. (US) 2003-01-03 WO disclosed
WO-2002087584-A1 COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS PFIZER PRODUCTS INC. (US) 2002-11-07 WO disclosed
WO-2002079198-A1 PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS PFIZER PRODUCTS INC. (US) 2002-10-10 WO disclosed
US-20020143017-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2002-10-03 US disclosed
EP-0869790-A4 THIENO(2,3-b)PYRAZOLO(3,4-d)PYRIDIN-3-ONES TO ENHANCE ERYTHROPOIESIS SMITHKLINE BEECHAM CORP (US) 2001-04-11 EP disclosed
US-6107304-A ANEMIA SMITHKLINE BEECHAM CORPORATION (US) 2000-08-22 US disclosed
EP-0869790-A1 THIENO(2,3-b)PYRAZOLO(3,4-d)PYRIDIN-3-ONES TO ENHANCE ERYTHROPOIESIS SMITHKLINE BEECHAM CORPORATION (US) 1998-10-14 EP disclosed
WO-1997024120-A1 THIENO(2,3-b)PYRAZOLO(3,4-d)PYRIDIN-3-ONES TO ENHANCE ERYTHROPOIESIS SMITHKLINE BEECHAM CORPORATION (US) 1997-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340565-A1 CD73 INHIBITOR COMPOUNDS ENTPD5, ENTPD1, NT5E DYRK1A 2400/4885CHEK1 3190/4885AURKA 2915/4885
US-20030162784-A1 Pyridazinone aldose reductase inhibitors SLC5A1, ALDOA, AKR1B1 DYRK1A 2569/4885CHEK1 4081/4885AURKA 3969/4885
US-20020143017-A1 Pyridazinone aldose reductase inhibitors SLC5A1, AKR1B1, AKR1D1 DYRK1A 3042/4885CHEK1 3742/4885AURKA 3903/4885
US-20240287076-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE BTK, SYK, LYN DYRK1A 139/4885CHEK1 580/4885AURKA 1265/4885
US-12404279-B2 Deubiquitinase inhibitors and methods of use thereof USP7, USP28, USP1 DYRK1A 2320/4885CHEK1 1022/4885AURKA 1773/4885
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 DYRK1A 3360/4885CHEK1 3131/4885AURKA 4705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.